Indole-3-Propionic Acid as a Potential Therapeutic Agent for Sepsis-Induced Gut Microbiota Disturbance

Heng Fang1,2,3, Miaoxian Fang2, Yirong Wang2

  • 1Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.

Insights

Indole-3-propionic acid (IPA), a gut microbiota metabolite, improved survival rates in septic mice by modulating gut bacteria. This suggests metabolites could be used instead of live microbes to treat sepsis-induced gut dysbiosis.

Area of Science:

  • Microbiology
  • Immunology
  • Gastroenterology

Background:

  • Gut microbiota plays a crucial role in sepsis pathophysiology.
  • Sepsis-induced gut dysbiosis is a significant factor in disease progression.
  • Current therapies targeting gut microbiota, like probiotics or fecal microbiota transplantation (FMT), have limitations.

Purpose of the Study:

  • To investigate the effects of indole-3-propionic acid (IPA), a gut microbiota metabolite, on sepsis-induced gut dysbiosis in mice.
  • To determine if IPA can modulate the gut microbiota and improve outcomes in a sepsis model.
  • To explore the potential of using microbiota metabolites as an alternative to live microorganisms for sepsis treatment.

Main Methods:

  • Sepsis models were induced in mice using cecal ligation and puncture (CLP).
  • Mice were treated with IPA or saline, with some groups receiving antibiotics.
  • Fecal microbiota composition was analyzed, and fecal microbiota transplantation (FMT) was performed to assess the role of gut microbiota.

Main Results:

  • IPA treatment significantly increased survival rates and reduced serum inflammatory mediators in septic mice.
  • IPA administration altered gut microbiota composition, enriching Bifidobacteriaceae and depleting Enterobacteriaceae.
  • The beneficial effects of IPA were negated by antibiotic treatment, and FMT from IPA-treated mice improved survival in recipients.
  • IPA did not increase overall microbial diversity but specifically reduced Enterobacteriaceae abundance.

Conclusions:

  • Indole-3-propionic acid (IPA) ameliorates sepsis-induced mortality and inflammation by modulating the gut microbiota.
  • Gut microbiota metabolites like IPA offer a potential therapeutic strategy for sepsis, serving as an alternative to live microbial interventions.
  • Targeting specific bacterial families, such as reducing Enterobacteriaceae, may be a key mechanism by which IPA exerts its protective effects in sepsis.

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
205
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
403
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
433
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
207
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
317